Drugs / rF1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00246467 | Oct 2005 → Apr 2007 | plague | PharmAthene UK Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rF1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00246467 ↗ |
| Modality | Protein / enzyme biologic | “rF1 and rV recombinant antigen proteins” NCT00246467 ↗ |
| Route | Intramuscular | “recombinant IM plague vaccine (rF1 and rV) antigen proteins” NCT00246467 ↗ |